Will Supreme Court Lift 'IPR Pressure' Off Biopharma?
This article was originally published in Scrip
Executive Summary
The US Supreme Court on Jan. 15 said it would hear a case to decide if the US Patent & Trademark Office (US PTO) Patent Trial and Appeal Board (PTAB) is using the proper standard when it determines the validity of a patent under so-called inter partes reviews (IPRs) and if the decisions to hold those proceedings should be judicially reviewable.